Skip to main content

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc is an American biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. The enterprise focuses on developing RNAi-based drugs targeting rare genetic, cardio-metabolic, and infectious diseases. Revenue is primarily generated from commercial product sales of proprietary medicines including Onpattro, Givlaari, Oxlumo, and Amvuttra, alongside strategic partnership royalties. Alnylam occupies a pioneering global leadership position as the premier commercial provider of RNAi therapeutics. Its primary end markets include academic medical centers, rare disease specialists, and patients affected by genetic disorders worldwide. The company is headquartered in Cambridge, Massachusetts, and its common stock is traded on the Nasdaq Stock Market.

46 of the funds FundTelligence covers report a position in Alnylam Pharmaceuticals.

Legal name
Alnylam Pharmaceuticals Inc.
Sector
Health Care
Country
United States
Funds holding it
46
Exposure themes
Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics

Funds holding Alnylam Pharmaceuticals

Showing the 8 largest of 46 funds holding it.

Loading...